LENSAR, Inc. (NASDAQ:LNSR) Short Interest Update

LENSAR, Inc. (NASDAQ:LNSR) saw a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 105,100 shares, a growth of 66.0% from the February 13th total of 63,300 shares. Currently, 1.2% of the shares of the company are sold short. Based on an average daily volume of 93,700 shares, the days-to-cover ratio is currently 1.1 days.

LENSAR Price Performance

Shares of LNSR stock traded up $0.53 on Friday, hitting $15.13. 130,806 shares of the stock traded hands, compared to its average volume of 112,453. The firm has a market cap of $178.37 million, a price-to-earnings ratio of -10.36 and a beta of 0.62. LENSAR has a 52 week low of $2.67 and a 52 week high of $16.40. The firm has a 50 day simple moving average of $10.72 and a two-hundred day simple moving average of $7.78.

LENSAR (NASDAQ:LNSR) last released its quarterly earnings results on Thursday, February 27th. The company reported ($1.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($1.40). LENSAR had a negative return on equity of 49.02% and a negative net margin of 34.03%. The firm had revenue of $16.73 million for the quarter, compared to analysts’ expectations of $14.95 million.

Institutional Trading of LENSAR

Hedge funds and other institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC lifted its holdings in LENSAR by 3.5% during the third quarter. Geode Capital Management LLC now owns 100,431 shares of the company’s stock valued at $460,000 after purchasing an additional 3,423 shares in the last quarter. Essex Investment Management Co. LLC lifted its holdings in LENSAR by 18.3% during the fourth quarter. Essex Investment Management Co. LLC now owns 39,890 shares of the company’s stock valued at $357,000 after purchasing an additional 6,184 shares in the last quarter. Evernest Financial Advisors LLC purchased a new position in LENSAR during the fourth quarter valued at $174,000. Bailard Inc. purchased a new position in shares of LENSAR in the fourth quarter worth about $181,000. Finally, Renaissance Technologies LLC lifted its stake in shares of LENSAR by 13.3% in the fourth quarter. Renaissance Technologies LLC now owns 348,891 shares of the company’s stock worth $3,119,000 after buying an additional 40,946 shares in the last quarter. Institutional investors and hedge funds own 40.15% of the company’s stock.

Analysts Set New Price Targets

Separately, Lake Street Capital boosted their price target on shares of LENSAR from $12.00 to $16.00 and gave the stock a “buy” rating in a research note on Friday, February 28th.

LENSAR Company Profile

LENSAR, Inc, a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision.